Strategies for incorporating resource allocation and economic considerations: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)

Chest

Volumn 133, Issue 6 SUPPL. 6, 2008, Pages 132S-140S

  Matchar, David B ^a,b   Mark, Daniel B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Ctr for Clin Hlth Policy Research   (United States)

Author keywords

Cost analysis; Cost effectiveness analysis; Costs; Health care costs; Practice guidelines

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH CARE RATIONING; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 45949090300     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0671     Document Type: Article

References (27)

1. Guyatt G, Baumann M, Pauker S, et al. Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. Chest 2006; 129:182-187
2. Garber A, Phelps C. Economic foundations of cost-effectiveness analyses. J Health Economics 1997; 16:1-31
3. Nord E. Cost-value analysis in health care. Cambridge, UK: Cambridge University Press, 1999; 23
4. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: similarities differences and some implications. Value in Health 2001; 4:225-250
5. Ellrodt AG, Conner L, Riedinger M, et al. Measuring and improving physician compliance with clinical practice guidelines: a controlled intervention trial. Ann Intern Med 1995; 122:277-282
6. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993; 306:570-572
7. Greenberg D, Rosen AB, Olchanski NV, et al. Delays in publications of cost-utility analyses conducted alongside clinical trials: registry analysis. BMJ 2004; 328:1536-1537
8. Sachs JD. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, Switzerland, 2001. Available at: http://whqlibdoc.who. int/publications/2001/924154550X.pdf. Accessed May 12, 2008
9. Matchar DB, Samsa CP. Linking health policy modeling with health policy formation and implementation. In: Chapman GB, Sonnenberg FA, eds. Decision making in health care: theory, psychology, and applications. Cambridge, UK: Cambridge University Press, 2000; 65-109
10. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford University Press, 2005; 27-51
11. Gold MR, Siegel JE, Russel LB, et al. eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996; 304-311
12. Geerts W, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl):381S-453S
13. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl):630S-669S
14. Harrrington RA, Beck RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl):670S-707S
15. Becker, Meod TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl):776S-814S
16. Sobel M, Verhaeghe R. Antithrombotic therapy in peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl):815S-842S
17. Detournay B, Planes A, Vochelle N, et al. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998; 13:81-89
18. Bergqvist D, Jonsson B. Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 1999; 2:288-294
19. Marchetti M, Liberato NL, Ruperto N, et al. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica 1999; 84:730-737
20. Friedman RJ, Dunsworth GA. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop 2000; 370:171-182
21. Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value in Health 2000; 3:397-406
22. Sarasin FP, Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. J Thromb Haemost 2002; 87:586-592
23. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a cost-utility analysis. Arch Orthop Trauma Surg 2004; 124:507-517
24. Weintraub W, Mahoney E, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005; 45:838-845
25. Schleinitz M, Heidenreich P. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005; 142:251-259
26. Gaspoz J, Coxson P, Goldman P, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800-1806
27. Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717